Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI

Title:Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI

Volume: 23 Issue: 9

Author(s): Manolis Vavuranakis*, Konstantinos Dean Boudoulas, Ourania Katsarou, Dimitrios A. Vrachatis, Konstantinos I. Kalogeras, Theodore G. Papaioannou, Gerasimos Siasos, Evangelos Oikonomou, George Lazaros, Michael-Andreas Vavuranakis, Spyridon Deftereos and Dimitrios Tousoulis

Affiliation:

• 13 Astypaleas, Anoixi, Attiki 14569,Greece

Keywords: ASD, LAA, PFO, transcatheter, warfarin, coumadin, antiplatelet, NOAC.

Abstract: Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.

Cite this article as:

Vavuranakis Manolis*, Boudoulas Dean Konstantinos, Katsarou Ourania, Vrachatis A. Dimitrios, Kalogeras I. Konstantinos, Papaioannou G. Theodore, Siasos Gerasimos, Oikonomou Evangelos, Lazaros George, Vavuranakis Michael-Andreas, Deftereos Spyridon and Tousoulis Dimitrios, Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161221143416